STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delive…
$25.21-5.65%
报价 2026-11-06
市值
$1.26B
EV
$983.2M
PE (TTM)
275.1x
预期 PE (FY2027)
80.5x
52 周区间距高点 -24.4%
$16.10$33.34
筛选结果
pipeline · 2026-11-06Keep✓ 高增长✗ Cheap✗ GARP
Growth Pool: next 1Y revenue growth > 30%
爆发潜力
2026-11-07未命中✗ 收入线✗ EPS 线
| 财年 | 收入倍数 | EPS | PE |
|---|---|---|---|
| FY+22028-01 | 1.1x | 0.45 → 0.58（1.3x） | 43.4 |
| FY+32029-01 | 1.2x | 0.45 → 0.69（1.5x） | 36.5 |
毛利率 76% · TTM 收入 $328M · 基数 EPS 0.45（调整后）
电话会信号
辅助标签Q3 20262026-11-04
扩产积压订单词频高盈利拐点供不应求
指引 无
信心 4
分析师 4
“We expect fourth quarter gross margin above third quarter and continued improvement in 2027 as unit costs improve with both facilities at full capacity.”
原文引用（3）
- 扩产：we expect that our yields to return to normal and to significantly increase
- 盈利拐点：we improved from an adjusted net loss in last year's third quarter to GAAP net income this quarter
- 供不应求：we were not yet able to fully meet the demand for lenses in the third quarter
蓝色标签在暴涨研究中略有区分度；悬停查看口径。
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| STAASTAAR Surgical Company | $1.26B | -5.7% | +31.5% | 74.5% | 275.1x | 29.7x | – | 高增长 |
| PLSEPulse Biosciences, Inc. | $3.87B | +0.4% | +1900.0% | 51.6% | – | – | – | 高增长 |
| AZTAAzenta, Inc. | $1.72B | +4.8% | +4.0% | 44.9% | – | – | 173.6x | |
| KMTSKESTRA MEDICAL TECHNOLOGIES, LTD. | $1.72B | +0.9% | +51.5% | 56.5% | – | – | – | 高增长 |
| PGENPrecigen, Inc. | $1.6B | +5.9% | +1715.6% | 89.6% | – | – | – | |
| NVCRNovoCure Limited | $1.55B | -2.0% | +12.9% | 77% | – | – | – | |
| ORICORIC Pharmaceuticals, Inc. | $914.2M | +3.9% | – | 0% | – | – | – | |
| BBNXBeta Bionics, Inc. | $706.3M | +1.4% | +35.5% | 58.6% | – | – | – | 高增长 |
| 同行中位数 | – | – | +43.5% | 56.5% | – | – | 173.6x |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
| Metric | 2026-07-03 Q2 2026 | 2026-04-03 Q1 2026 | 2026-01-02 Q4 2025 | 2025-09-26 Q3 2025 | 2025-06-27 Q2 2025 | 2025-03-28 Q1 2025 | 2024-12-27 Q4 2024 | 2024-09-27 Q3 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $93.5M | $93.5M | $57.8M | $94.7M | $44.3M | $42.6M | $49M | $88.6M |
| Gross Margin | 74.5% | 72.2% | 75.7% | 82.2% | 74% | 65.8% | 64.7% | 77.3% |
| Operating Margin | 10.8% | 18.6% | -18.9% | 19.5% | -67.6% | -134.8% | -57% | 6.4% |
| Net Income | $8.1M | $5.2M | $-18.3M | $8.9M | $-16.8M | $-54.2M | $-34.2M | $10M |
| Diluted EPS | 0.16 | 0.1 | -0.36 | 0.18 | -0.34 | -1.1 | -0.69 | 0.2 |
| Operating Cash Flow | $19.7M | $-21.7M | $-3.9M | $2.7M | $-27.2M | $-5.7M | $642,000 | $3.8M |